These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 8649546

  • 1. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
    Carpentier AF, Bonnet AM, Vidailhet M, Agid Y.
    Neurology; 1996 Jun; 46(6):1548-51. PubMed ID: 8649546
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K.
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [Abstract] [Full Text] [Related]

  • 3. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N, Viallet F, Boulamery A, Eusebio A, Gayraud D, Azulay JP.
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [Abstract] [Full Text] [Related]

  • 4. How best to address these common movement disorders.
    Yaman A, Akdeniz M, Yaman H.
    J Fam Pract; 2011 Dec; 60(12):721-5. PubMed ID: 22163354
    [No Abstract] [Full Text] [Related]

  • 5. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Dec; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 6. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S, Pradhan R, Paul P, Das M, Gupta A, Ghosh P, Chatterjee S.
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [Abstract] [Full Text] [Related]

  • 7. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ.
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [Abstract] [Full Text] [Related]

  • 8. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C.
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [Abstract] [Full Text] [Related]

  • 9. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations.
    Jankovic J.
    Mov Disord; 2005 Nov; 20 Suppl 11():S11-6. PubMed ID: 15822109
    [Abstract] [Full Text] [Related]

  • 10. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG, Stebbins GT, Blasucci LM.
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease.
    Nicoletti A, Mostile G, Nicoletti G, Arabia G, Iliceto G, Lamberti P, Marconi R, Morgante L, Barone P, Quattrone A, Zappia M.
    J Neurol; 2016 May; 263(5):888-894. PubMed ID: 26964541
    [Abstract] [Full Text] [Related]

  • 13. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Rocha MS, Andrade LA, Ferraz HB, Borges V.
    Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765
    [Abstract] [Full Text] [Related]

  • 14. Preventing and controlling dyskinesia in Parkinson's disease--a view of current knowledge and future opportunities.
    Jenner P.
    Mov Disord; 2008 Dec; 23 Suppl 3():S585-98. PubMed ID: 18781676
    [Abstract] [Full Text] [Related]

  • 15. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.
    Nutt JG, Carter JH, Lea ES, Woodward WR.
    Mov Disord; 1997 May; 12(3):285-92. PubMed ID: 9159720
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease.
    Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J.
    Mov Disord; 2004 May; 19(5):554-60. PubMed ID: 15133820
    [Abstract] [Full Text] [Related]

  • 20. Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease.
    Müller T, Woitalla D, Russ H, Hock K, Haeger DA.
    J Neural Transm (Vienna); 2007 May; 114(8):1023-6. PubMed ID: 17417738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.